ACCELERATING THE DEVELOPMENT OF NEW GENOMIC SOLUTIONS FOR CANCER.
We believe our unique data sharing platform creates a network effect among its users to rapidly develop and validate new genomic solutions to answer critical clinical questions. The Decipher GRID program aims to improve cancer patient care by harnessing the power of collaboration.
GENOMICS RESOURCE INFORMATION DATABASE (GRID)
The Decipher GRID research program features what we believe is the fastest growing tumor RNA expression database for urologic cancers with over 27,000 genomic profiles. Each profile consists of over 1.4 million markers covering 46,000 coding and non-coding genes and contains the patient demographics, clinical information and pathology features. Through this innovative data sharing and collaborative research platform, the GRID program has already contributed to over 45 scientific publications and several novel genomic solutions used in the clinic today. The GRID program serves as a rich resource to the urology and oncology communities that aims to transform the treatment and management of cancer.
DECIPHER GENOMIC CANCER CLASSIFIERS
The Decipher cancer classifiers are CLIA-certified, laboratory developed tests that utilize genomic expression information to provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making. The Decipher assay captures a high resolution view of the transcriptome with over 1.4 million data points per tumor, enabling new GRID discoveries. Once validated these genomic solutions then become available for clinical use.
REIMAGINING THE USE OF GENOMIC INFORMATION
GenomeDx uses the power of collaborative genomics to transform the management and treatment of cancer patients. By analyzing large amounts of complex data, GenomeDx is developing tools that enhance the way patient care is managed. Our goal is to increase the efficiency of practice management, optimizing decision-making related to patient care, and improving outcomes for our patients.
Through the capture, analysis and exchange of genomic information, GenomeDx is working to change the way cancer is understood.
FOR YOUR PATIENTS
By ordering the Decipher cancer classifiers, a physician can also access the GRID Tumor RNA Expression Profile to further explore the patient's tumor biology. GRID profiles include over 70 genes and signatures that reveal the tumor's molecular subtypes and active biological pathways as well as predicting tumor stage, recurrence risk and response to therapy.
This RESEARCH USE ONLY data has been developed by our extensive network of research collaborators or curated from literature. GRID genomic markers and signatures are being tested in ongoing clinical trials and once validated will be available for routine clinical use.
FOR YOUR CLINICAL RESEARCH
The primary objective of the Decipher GRID program is to foster data sharing and research collaborations in order to better understand cancer tumor biology with genomic data. Together, we can accelerate discovery and translation of new genomic solutions into the clinic.
In addition to the GRID Tumor RNA Expression Profile, researchers can receive a Dynamic Database that aggregates the expression levels, percentile rank and outlier calls for hundreds of genes and signatures for all your Decipher patients.
If you’d like to discuss the opportunity to partner with us for a research study, please contact us to obtain access to even more GRID data.
PARTICIPATE IN ADVANCING CANCER RESEARCH
Every tumor is unique. The Decipher assay measures over 1.4 million expression markers from your tumor tissue. In addition to your Decipher cancer classifier results, you can receive your GRID tumor profile, which can be used to better characterize your tumor and may help your physician to better personalize your cancer care. In addition, by participating in the GRID program you are contributing to research that advances the understanding of cancer that we believe will accelerate new ways to combat cancer.
Talk to your doctor today about the Decipher Cancer Classifiers and GRID program
With over 300 GRID physicians, our network continues to grow feeding more data into the GRID to power new discoveries in cancer. To find a physician near you, please contact us.
Decipher GRID is a hub in cancer research and has been used in more than 45 clinical studies published in collaboration with over 55 leading cancer centers.
Our GRID patient population is growing by approximately 1,300 tumor profiles a month.
HOW TO ACCESS GRID RESEARCH PROFILES
Order the Decipher Test and receive access to your patient's GRID Tumor RNA Expression Profile.
Become a GRID physician and you can receive the Dynamic Database* for all your patients.
* Available once you order 10 Decipher Tests.
If you are already part of our GRID physician network and want to access your GRID results, please click here.
GRID PROFILES FOR
HOW TO ACCESS GRID RESEARCH DATA
If you are currently ordering the Decipher Test and would like to become a GRID researcher, please contact your sales representative to discuss how to join our program.
If you are interested in joining the GRID research program and are NOT currently ordering Decipher tests, please complete the following contact form and provide additional information about your research interests. A GenomeDx representative will reach out to discuss the next steps.
GRID DATA FOR YOUR
HOW TO ACCESS YOUR TUMOR PROFILE
The GRID program is available to patients who have had the Decipher test performed. If you have not had this test ordered, please discuss with your physician or contact us to be connected with a GRID physician.
If you have had the Decipher test performed, please contact your physician to request your GRID profile or contact us.
DECIPHER GRID TECHNOLOGY + PUBLICATIONS
TRANSCRIPTIONAL PROFILING OF TUMORS
The Decipher assay is performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples using microarray technology to capture the expression levels for over 46,000 coding and non-coding genes across the genome. From over 1.4 million expression markers measured, a subset of markers are used in a proprietary algorithm to compute the Decipher cancer classifier score. After de-identification, the entire expression profile is processed through our GRID analysis pipeline. The raw data and normalized expression levels are stored within the GRID database and made available to researchers for further analyses.
Klein E.A., et al. Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential. Journal of Urology. 2017 Jan; 197(1):122-128. doi: 10.1016/j.juro.2016.08.091.
Ross A.E., et al. Tissue Based Genomics Augments Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. 2016 Jan; 69(1): 157-65. doi: 10.1016/j.eururo.2015.05.042. PMID: 26058959
Prensner J.R., et al. RNA Biomarkers Associated with Metastatic Progression in Prostate Cancer: a Multi-Institutional High-Throughput Analysis of SChLAP1. Lancet Oncol. 2014 Dec; 15(13): 1469-80. doi: 10.1016/S1470-2045(14)71113-1.
Karnes R.J., et al. Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. The Journal of Urology. 2013 Dec; 190(6): 2047-53. doi: 10.1016/j.juro.2013.06.017.
Den R.B., at al. Decipher correlation patterns post-prostatectomy: Initial experience from 2,342 prospective patients. Prostate Cancer and Prostatic Disease. 2016 Dec;19(4):374-379.doi: 10.1038/pcan.2016.38.
Benzon B., et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer and Prostatic Disease. 2016 Nov. doi: 10.1038/pcan.2016.49.
Zhao S.G., et al. The Development and Validation of a 24-gene Predictor of Response to Post-operative Radiation Therapy in Prostate Cancer: A Matched Retrospective Analysis. Lancet Oncology. 2016 Nov; 17(11):1612-1620. doi: 10.1016/S1470-2045(16)30491-0.
Johnson M.H., et al., SPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at-risk, natural history radical prostatectomy cohort. Journal of Urology. 2016 Nov; 196(5):1436-1444. doi: 10.1016/j.juro.2016.05.092.